Valerie A. Muthig

BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naïve mantle cell lymphoma.

A. Ruppert, M. Dreyling, C. Cheah, 2022, Future oncology.

MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress).

Michael L. Wang, M. Dreyling, C. Cheah, 2021, Clinical lymphoma, myeloma & leukemia.